FIREFLY BIOWORKS
Firefly BioWorks, Inc. (Cambridge, MA) is introducing an open platform allowing industrial, academic and clinical scientists to develop and use multiplexed biological assays on standard laboratory instrumentation. The company's core technology, Optical Liquid Stamping, was developed in the Chemical Engineering Department at MIT (News - Alert) by Firefly co-founders. The method allows rapid and scalable synthesis of encoded, multi-functional particles for the quantification of biological function. The company's long-term vision is to provide research and clinical scientists with reliable and affordable solutions for the comprehensive monitoring of biological systems.
FIREFLY BIOWORKS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.fireflybio.com
Total Employee:
11+
Status:
Active
Contact:
6175006246
Email Addresses:
[email protected]
Total Funding:
3.4 M USD
Technology used in webpage:
SPF SSL By Default Apache Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Sectigo SSL Sectigo Domain SSL Mimecast PairNetworks DNS
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Current Advisors List
Founder
Investors List
Massachusetts Life Sciences Center
Massachusetts Life Sciences Center investment in Grant - Firefly BioWorks
Sands Capital Ventures
Sands Capital Ventures investment in Venture Round - Firefly BioWorks
More informations about "Firefly BioWorks"
Firefly Bio - Crunchbase Company Profile & Funding
Organization. Firefly Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Firefly Bio specializes in Degrader Antibody …See details»
Firefly Bio | ADCs reimagined
Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders. Our state-of-the-art platform results in highly specific delivery of degraders to target tissue.See details»
About Our Team - Firefly Bio
In addition to his academic research, Devin served as part of the inaugural leadership team of the MIT Biotech Group, which has since grown into the largest life-sciences student organization at MIT. Devin is originally from Fresno, CA, …See details»
FireflyBio - Products, Competitors, Financials, Employees, …
When was FireflyBio founded? FireflyBio was founded in 2022. Where is FireflyBio's headquarters? FireflyBio's headquarters is located at 2 Tower Place, South San Francisco. …See details»
Firefly Bio - Funding, Financials, Valuation & Investors - Crunchbase
Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.See details»
FireFly Bio Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for FireFly Bio. Use the PitchBook Platform to explore the full profile.See details»
Firefly Bio - LinkedIn
Firefly Bio Biotechnology Research South San Francisco, California 7,769 followers Realizing the full potential of ADCs by unlocking new classes of payloadsSee details»
FireflyBio - Overview, News & Similar companies | ZoomInfo.com
FireflyBio is a company that operates in the Internet industry. It employs 11-20 people and has $1M-$5M of revenue. Is this data correct? View contact profiles from FireflyBio. Popular …See details»
Firefly BioWorks - Crunchbase Company Profile
Contact Email [email protected] Phone Number 6175006246 Firefly BioWorks, Inc. (Cambridge, MA) is introducing an open platform allowing industrial, academic and clinical scientists to develop and use multiplexed biological …See details»
Firefly Bio Company Profile - Office Locations, Competitors ... - Craft
Firefly Bio has 5 employees at their 1 location and $94 m in total funding,. See insights on Firefly Bio including office locations, competitors, revenue, financials, executives, subsidiaries and …See details»
FireflyBio Company Profile | Management and Employees List
FireflyBio is a company that operates in the Internet industry. It employs 11-20 people and has $1M-$5M of revenue. Popular Searches. FireflyBio. Primary Industries. Manufacturing …See details»
Firefly BioWorks Company Profile | Management and Employees …
[email protected]: Firefly BioWorks Top Competitors. Company Employees Revenue Top technologies; MGB Biopharma Ltd. n/a: $3.9 M: Mnemosyne Pharmaceuticals Inc. 18: $3.9 M: …See details»
Press Release | Firefly Bio Debuts With $94 Million Series A Financing
Feb 15, 2024 Firefly Bio Debuts With $94 Million Series A Financing — T ransformational degrader antibody conjugate company b acked by leading syndicate including founding …See details»
Firefly Bio Debuts With $94 Million Series A Financing - Yahoo …
Feb 15, 2024 SOUTH SAN FRANCISCO, Calif., February 15, 2024--Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant …See details»
Firefly Bio assembles with $94M and an ADC dream team to work …
May 30, 2024 The idea to build a company around degrader-antibody conjugates (DACs)—not to be confused with antibody-drug conjugates (ADCs)—has been bubbling for a while. But not …See details»
Firefly Bio assembles with $94M and an ADC dream team - Fierce …
Feb 15, 2024 A little waiting brought together a dream team. Scott Hirsch, who previously served as chief operating officer at Allakos and did time at Genentech and AbbVie, will serve as CEO; …See details»
ADC-Focused Firefly Bio Emerges from Stealth with $94M Series A
Feb 15, 2024 Pictured: 3D rendering of Antibody Drug Conjugate molecules, with cytotoxic payload/iStock, Marcin Klapczynski California-based startup Firefly Bio announced Thursday …See details»
Firefly Bio Launches with $94 Million for Innovative Cancer Therapy ...
Mar 1, 2024 Firefly Bio has launched with $94 million in Series A funding, introducing a novel platform utilizing degrader antibody conjugates (DACs) aimed at cancer treatment.See details»
Firefly Bio emerges from stealth to develop degrader-antibody …
Feb 15, 2024 “The idea is pretty simple—can we improve ADCs by delivering more-selective payloads,” says Scott Hirsch, Firefly’s CEO. ADCs first entered clinical trials about 40 years …See details»
Firefly BioWorks Company Profile 2024: Valuation, Investors ...
Firefly BioWorks General Information Description. Developer of a multiplex assay platform intended to detect biomarkers. The company provides an open platform allowing industrial, …See details»